{
  "pmcid": "PMC11730665",
  "title": "Comparative efficacy and safety of sitagliptin or gliclazide combined with metformin in treatment-naïve patients with type 2 diabetes mellitus",
  "description": "Treatment-naive patients with type 2 diabetes mellitus study",
  "studyType": "Clinical trial, prospective",
  "participants": 129,
  "study_parameters": {
    "summary": "This study evaluates the efficacy and safety of sitagliptin versus gliclazide, combined with metformin, in treatment-naïve patients with T2DM.",
    "study_type": {
      "content": "Clinical trial, prospective",
      "explanation": "The study is described as a 'single-center, prospective, randomized, controlled noninferiority trial'.",
      "quotes": [
        "In this single-center, randomized, controlled noninferiority trial, 129 treatment-naïve patients with T2DM with glucotoxicity",
        "This single-center, prospective, randomized, controlled, noninferiority study..."
      ]
    }
  },
  "participant_info": {
    "content": "129 treatment-naïve patients with type 2 diabetes mellitus (T2DM) and glucotoxicity, aged 18 to 70 years",
    "explanation": "The study included 129 treatment-naïve patients with T2DM and glucotoxicity, aged 18 to 70 years, with specific inclusion criteria.",
    "quotes": [
      "129 treatment-naïve patients with T2DM with glucotoxicity (fasting plasma glucose [FPG] ≥ 200 mg/dL and glycated hemoglobin [HbA1c] ≥ 9%)",
      "The age range is between 18 and 70 years, with a body mass index (BMI) ranging from 18 to 30 kg/m²..."
    ]
  },
  "study_design": {
    "content": "The study was conducted at Nanfang Hospital of Southern Medical University, involving 129 participants randomized to receive different treatments.",
    "explanation": "The study design is detailed as a randomized controlled trial with two groups, each receiving different treatment combinations.",
    "quotes": [
      "In this single-center, randomized, controlled noninferiority trial, 129 treatment-naïve patients with T2DM with glucotoxicity",
      "Participants were recruited from Nanfang Hospital of Southern Medical University between September 1, 2023, and March 31, 2024, and were randomized to receive sitagliptin plus metformin (n = 66) or gliclazide plus metformin (n = 63) for 12 weeks."
    ]
  },
  "treatment_groups": {
    "sitagliptin_metformin": {
      "participants": 66,
      "dosage": "Sitagliptin 100mg + Metformin",
      "duration": "12 weeks"
    },
    "gliclazide_metformin": {
      "participants": 63,
      "dosage": "Gliclazide + Metformin",
      "duration": "12 weeks"
    }
  },
  "primary_endpoints": {
    "hba1c_reduction": "Significant improvement in both groups",
    "fasting_glucose": "Comparable reduction between groups",
    "safety_profile": "Well-tolerated with minimal adverse events"
  }
}